Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Nouvelle Place Begins Senior Contract MRs Dispatching Business
December 7, 2009
- Many Patients with Depression Need Treatment for Pain: Dr Shimodera
December 7, 2009
- Glufast Approved in China: Kissei
December 7, 2009
- Switch OTC Recommended for Loxoprofen
December 7, 2009
- Japan Should Establish National Vaccine Plan: Mr Feliciano
December 7, 2009
- Abilify Approved for Irritability in Children with Autistic Disorders in US
December 7, 2009
- Ketotifen Nasal Drops Reclassified as Class 2 OTC Drug
December 7, 2009
- Diovan Back to Top Place on GP Market: Rep Track Survey
December 7, 2009
- Eisai Applies for Aricept Extended-Release Tablets in US
December 7, 2009
- OPINION／How Marketing Moves in Mysterious Ways
December 7, 2009
- Dutch Industry-Academia Alliances for Bio-Based Innovation Highlighted
December 7, 2009
- Silodosin Recommended for Approval in EU: Kissei
December 7, 2009
- Blue Letter Required for Nexavar
December 7, 2009
- Pfizer, Astellas Launch Caduet Combination Tablets
December 7, 2009
- AnGes Agrees with FDA on SPA for PIII Trial of Collategene
December 7, 2009
- Effectively Use DB for Pharmacovigilance: Dr Chan
December 7, 2009
- Abbott Acquires Global Rights to Biologic Pain Killer from PanGenetics
December 7, 2009
- Otsuka Withdraws Application for Abilify for Major Depression in Europe
December 7, 2009
- Price Maintenance System Essential to Promote Drug Industry: Mr Nagayama
December 7, 2009
- Sanofi-aventis, Regeneron Expand Strategic Antibody Collaboration
December 7, 2009
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…